Patents by Inventor Andrew Damokosh

Andrew Damokosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
    Publication number: 20220235121
    Abstract: Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 28, 2022
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Lori Payton, Christian Mix, Rajendra Pradhan, Andrew Damokosh, Eugene Scott Swenson, Xiang Gao
  • DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
    Publication number: 20200254092
    Abstract: Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.
    Type: Application
    Filed: October 26, 2018
    Publication date: August 13, 2020
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Lori PAYTON, Scott T. ROTTINGHAUS, Rajendra PRADHAN, Andrew DAMOKOSH, Xiang GAO
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20100009358
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
    Type: Application
    Filed: December 18, 2008
    Publication date: January 14, 2010
    Applicants: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Mark D. Ayers, Jim Stec, Andrew Damokosh, Edwin Clark, Kenneth R. Hess, Gabriel N. Hortobagyi, Lajos Pusztai, W. Fraser Symmans, Robert C. Bast, JR.
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Patent number: 7504222
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: March 17, 2009
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas
    Inventors: Mark D. Ayers, Jim Stec, Andrew Damokosh, Edwin Clark, Kenneth R. Hess, Gabriel N. Hortobagyi, Lajos Pusztai, W. Fraser Symmans, Robert C. Bast, Jr.
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Publication number: 20080064055
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.
    Type: Application
    Filed: August 9, 2007
    Publication date: March 13, 2008
    Inventors: Barbara Bryant, Andrew Damokosh, George Mulligan
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Publication number: 20060281122
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: June 8, 2006
    Publication date: December 14, 2006
    Inventors: Barbara Bryant, Andrew Damokosh, George Mulligan
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20030219767
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
    Type: Application
    Filed: October 31, 2002
    Publication date: November 27, 2003
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., M.D. Anderson Cancer Center
    Inventors: Mark D. Ayers, Jim Stec, Andrew Damokosh, Edwin Clark, Kenneth R. Hess, Gabriel N. Hortobagyi, Lajos Pusztai, W. Fraser Symmans